Literature DB >> 33794365

FOSL1 promotes metastasis of head and neck squamous cell carcinoma through super-enhancer-driven transcription program.

Ming Zhang1, Rosalie G Hoyle2, Zhikun Ma2, Bo Sun2, Weixin Cai2, Hongshi Cai1, Nan Xie3, Yadong Zhang1, Jinsong Hou1, Xiqiang Liu4, Demeng Chen5, Glen E Kellogg6, Hisashi Harada7, Yue Sun7, Cheng Wang8, Jiong Li9.   

Abstract

Previously, we discovered that FOSL1 facilitates the metastasis of head and neck squamous cell carcinoma (HNSCC) cancer stem cells in a spontaneous mouse model. However, the molecular mechanisms remained unclear. Here, we demonstrated that FOSL1 serves as the dominant activating protein 1 (AP1) family member and is significantly upregulated in HNSCC tumor tissues and correlated with metastasis of HNSCC. Mechanistically, FOSL1 exerts its function in promoting tumorigenicity and metastasis predominantly via selective association with Mediators to establish super-enhancers (SEs) at a cohort of cancer stemness and pro-metastatic genes, such as SNAI2 and FOSL1 itself. Depletion of FOSL1 led to disruption of SEs and expression inhibition of these key oncogenes, which resulted in the suppression of tumor initiation and metastasis. We also revealed that the abundance of FOSL1 is positively associated with the abundance of SNAI2 in HNSCC and the high expression levels of FOSL1 and SNAI2 are associated with short overall disease-free survival. Finally, the administration of the FOSL1 inhibitor SR11302 significantly suppressed tumor growth and lymph node metastasis of HNSCC in a patient-derived xenograft model. These findings indicate that FOSL1 is a master regulator that promotes the metastasis of HNSCC through a SE-driven transcription program that may represent an attractive target for therapeutic interventions.
Copyright © 2021 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FOSL1; HNSCC; metastasis; super-enhancer

Mesh:

Substances:

Year:  2021        PMID: 33794365      PMCID: PMC8353207          DOI: 10.1016/j.ymthe.2021.03.024

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   12.910


  68 in total

1.  CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation.

Authors:  Reyaz Ur Rasool; Ramakrishnan Natesan; Qu Deng; Shweta Aras; Priti Lal; Samuel Sander Effron; Erick Mitchell-Velasquez; Jessica M Posimo; Shannon Carskadon; Sylvan C Baca; Mark M Pomerantz; Javed Siddiqui; Lauren E Schwartz; Daniel J Lee; Nallasivam Palanisamy; Goutham Narla; Robert B Den; Matthew L Freedman; Donita C Brady; Irfan A Asangani
Journal:  Cancer Discov       Date:  2019-08-29       Impact factor: 39.397

2.  Tumor budding correlates with poor prognosis and epithelial-mesenchymal transition in tongue squamous cell carcinoma.

Authors:  Cheng Wang; Hongzhang Huang; Zhiquan Huang; Anxun Wang; Xiaohua Chen; Lei Huang; Xiaofeng Zhou; Xiqiang Liu
Journal:  J Oral Pathol Med       Date:  2011-04-12       Impact factor: 4.253

Review 3.  The mechanisms behind the therapeutic activity of BET bromodomain inhibition.

Authors:  Junwei Shi; Christopher R Vakoc
Journal:  Mol Cell       Date:  2014-06-05       Impact factor: 17.970

4.  Master transcription factors and mediator establish super-enhancers at key cell identity genes.

Authors:  Warren A Whyte; David A Orlando; Denes Hnisz; Brian J Abraham; Charles Y Lin; Michael H Kagey; Peter B Rahl; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

5.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

6.  SNAI2/Slug promotes growth and invasion in human gliomas.

Authors:  Hong Wei Yang; Lata G Menon; Peter M Black; Rona S Carroll; Mark D Johnson
Journal:  BMC Cancer       Date:  2010-06-17       Impact factor: 4.430

Review 7.  AP-1--The Jun proteins: Oncogenes or tumor suppressors in disguise?

Authors:  Eitan Shaulian
Journal:  Cell Signal       Date:  2010-01-11       Impact factor: 4.315

Review 8.  Movers and shakers: cell cytoskeleton in cancer metastasis.

Authors:  C M Fife; J A McCarroll; M Kavallaris
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

9.  Inflammatory signals from photoreceptor modulate pathological retinal angiogenesis via c-Fos.

Authors:  Ye Sun; Zhiqiang Lin; Chi-Hsiu Liu; Yan Gong; Raffael Liegl; Thomas W Fredrick; Steven S Meng; Samuel B Burnim; Zhongxiao Wang; James D Akula; William T Pu; Jing Chen; Lois E H Smith
Journal:  J Exp Med       Date:  2017-05-02       Impact factor: 14.307

10.  Oncogenic RAS directs silencing of tumor suppressor genes through ordered recruitment of transcriptional repressors.

Authors:  Narendra Wajapeyee; Sunil K Malonia; Rajendra K Palakurthy; Michael R Green
Journal:  Genes Dev       Date:  2013-10-08       Impact factor: 11.361

View more
  10 in total

1.  FOSL1 promotes proneural-to-mesenchymal transition of glioblastoma stem cells via UBC9/CYLD/NF-κB axis.

Authors:  Zhengxin Chen; Shuai Wang; Hai-Lin Li; Hui Luo; Xiaoting Wu; Jiacheng Lu; Hong-Wei Wang; Yuanyuan Chen; Dan Chen; Wen-Ting Wu; Shuyu Zhang; Qiongqiong He; Daru Lu; Ning Liu; Yongping You; Wei Wu; Huibo Wang
Journal:  Mol Ther       Date:  2022-03-26       Impact factor: 12.910

2.  EHF is a novel regulator of cellular redox metabolism and predicts patient prognosis in HNSCC.

Authors:  Akinsola Oyelakin; Kasturi Bala Nayak; Alexandra Ruth Glathar; Christian Gluck; Theresa Wrynn; Antonio Tugores; Rose-Anne Romano; Satrajit Sinha
Journal:  NAR Cancer       Date:  2022-05-27

3.  Melatonin inhibits EMT and PD-L1 expression through the ERK1/2/FOSL1 pathway and regulates anti-tumor immunity in HNSCC.

Authors:  Xinyue Luo; Yang Chen; Hokeung Tang; Hui Wang; Erhui Jiang; Zhe Shao; Ke Liu; Xiaocheng Zhou; Zhengjun Shang
Journal:  Cancer Sci       Date:  2022-05-29       Impact factor: 6.518

4.  Verdinexor, a Selective Inhibitor of Nuclear Exportin 1, Inhibits the Proliferation and Migration of Esophageal Cancer via XPO1/c-Myc/FOSL1 Axis.

Authors:  Ling Ou; Xinyou Wang; Shumin Cheng; Min Zhang; Ruiqin Cui; Chunxia Hu; Shiyi Liu; Qian Tang; Yuying Peng; Ruihuan Chai; Shouxia Xie; Shaoxiang Wang; Wei Huang; Xiao Wang
Journal:  Int J Biol Sci       Date:  2022-01-01       Impact factor: 6.580

5.  Screening and cellular validation of prognostic genes regulated by super enhancers in oral squamous cell carcinoma.

Authors:  Liru Zhang; Huanju Li; Yongle Qiu; Yuanhang Liu; Xin Liu; Wenjing Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

6.  Transcriptomic Portraits and Molecular Pathway Activation Features of Adult Spinal Intramedullary Astrocytomas.

Authors:  Nikolay Konovalov; Stanislav Timonin; Dmitry Asyutin; Mikhail Raevskiy; Maxim Sorokin; Anton Buzdin; Stanislav Kaprovoy
Journal:  Front Oncol       Date:  2022-03-21       Impact factor: 6.244

7.  MiR-195-5p suppresses the proliferation, migration, and invasion of gallbladder cancer cells by targeting FOSL1 and regulating the Wnt/β-catenin pathway.

Authors:  Hongquan Zhu; Zhiping Chen; Jiandong Yu; Jiayan Wu; Xianhua Zhuo; Qin Chen; Yongling Liang; Guolin Li; Yunle Wan
Journal:  Ann Transl Med       Date:  2022-08

Review 8.  The Fra-1: Novel role in regulating extensive immune cell states and affecting inflammatory diseases.

Authors:  Yu-Yao He; Hai-Feng Zhou; Lu Chen; Yan-Ting Wang; Wan-Li Xie; Zhen-Zhen Xu; Yue Xiong; Yi-Qi Feng; Guo-Yang Liu; Xia Li; Jie Liu; Qing-Ping Wu
Journal:  Front Immunol       Date:  2022-08-11       Impact factor: 8.786

9.  FOSL1 promotes tumor growth and invasion in ameloblastoma.

Authors:  Gan Xiong; Shengqi Ouyang; Nan Xie; Jiaxiang Xie; Wenjin Wang; Chen Yi; Ming Zhang; Xiuyun Xu; Demeng Chen; Cheng Wang
Journal:  Front Oncol       Date:  2022-09-15       Impact factor: 5.738

Review 10.  The Fra-1/AP-1 Oncoprotein: From the "Undruggable" Transcription Factor to Therapeutic Targeting.

Authors:  Laura Casalino; Francesco Talotta; Amelia Cimmino; Pasquale Verde
Journal:  Cancers (Basel)       Date:  2022-03-14       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.